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Edited by Horst FeldmannAbstract Breast cancer is a heterogeneous disease that encom-
passes a wide range of histopathological types including: invasive
ductal carcinoma, lobular carcinoma, medullary carcinoma,
mucinous carcinoma, tubular carcinoma, and apocrine carcinoma
among others. Pure apocrine carcinomas represent about 0.5% of
all invasive breast cancers according to the Danish Breast Cancer
Cooperative Group Registry, and despite the fact that they are
morphologically distinct from other breast lesions, there are at
present no standard molecular criteria available for their diagno-
sis. In addition, the relationship between benign apocrine changes
and breast carcinoma is unclear and has been amatter of discussion
for many years. Recent proteome expression proﬁling studies of
breast apocrine macrocysts, normal breast tissue, and breast
tumours have identiﬁed speciﬁc apocrine biomarkers [15-hydroxy-
prostaglandin dehydrogenase (15-PGDH) and hydroxymethyl-
glutaryl coenzyme A reductase (HMG-CoA reductase)] present
in early and advanced apocrine lesions. These biomarkers in com-
binationwith proteins found to be characteristically upregulated in
pure apocrine carcinomas (psoriasin, S100A9, and p53) provide a
protein expression signature distinctive for benign apocrine meta-
plasias and apocrine cystic lesions. These studies have also pre-
sented compelling evidence for a direct link, through the
expression of the prostaglandin degrading enzyme 15-PGDH, be-
tween early apocrine lesions and pure apocrine carcinomas.More-
over, speciﬁc antibodies against the components of the expression
signature have identiﬁed precursor lesions in the linear histological
progression to apocrine carcinoma. Finally, the identiﬁcation of
proteins that characterize the early stages of mammary apocrine
diﬀerentiation such as 15-PGDH, HMG-CoA reductase, and
cyclooxygenase 2 (COX-2) has opened a window of opportunity
for pharmacological intervention, not only in a therapeuticmanner
but also in a chemopreventive setting. Here we review published
and recent results in the context of the current state of research
on breast apocrine cancer.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Breast cancer is the leading cause of cancer deaths in women
today and is the most common cancer among women in the
Western world (22% of all cancers). According to the World
Health Organization, more than 1.2 million people will be
diagnosed with breast cancer this year worldwide and the Dan-
ish Health authorities estimate that in 2005, approximately
4200 women were diagnosed with the disease in Denmark.
Moreover, there is a signiﬁcant increase in the number of
new cases diagnosed every year in Denmark as in the past 40
years the number of cases has tripled. Routine mammography
screening has increased the number of breast lesions detected,
but clearly, in spite of many eﬀorts, new strategies for early
detection, prevention and treatment are needed in order to
control the disease and improve survival.
Breast cancer is a heterogeneous disease that encompasses a
wide range of histopathological types including invasive ductal
carcinoma (IDC), lobular carcinoma (ILC), medullary carci-
noma, mucinous carcinoma, tubular carcinoma, and apocrine
carcinoma among others [1]. Apocrine carcinoma is a rare le-
sion that represents about 0.5% of all invasive breast carcino-
mas according to the Danish Breast Cancer Cooperative
Group (DBCG) Registry, and even though these lesions are
morphologically distinct from other breast carcinomas, there
are at present no available standard histopathological criteria
for their diagnosis [2–4] and as a result, there is no precise
information as to their prognosis. Molecular proﬁling of breast
cancer tumours with cDNA microarrays have provided a new
way to classify breast tumours in subgroups based on their
expression patterns [5], as well as to derive signatures for prog-
nosis [6–8] and response to treatment [9–11]. The original Stan-
ford classiﬁcation [5], subsequently reﬁned by Sorlie and
colleagues [12], describes ﬁve tumour sub-classes with charac-
teristic molecular features and clinical outcomes. The ﬁve types
deﬁned as: luminal A, luminal B, basal, normal and ERBB2,
represent distinct biological entities that with the exception
of the ERBB2 class can be related to cell type and diﬀerentia-
tion status. The Stanford classiﬁcation, however, is by no
means exhaustive as recently Farmer and colleagues [13] using
principal component analysis and hierarchical clustering
analysis of cDNA microarray data identiﬁed a novel subset
of breast tumours with increased androgen signalling andblished by Elsevier B.V. All rights reserved.
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crine’’, as these lesions do not exhibit all the histopathological
features of classical apocrine carcinomas. Molecular apocrine
tumours share some common expression characteristics with
the ERBB2 class in the Stanford classiﬁcation and exhibit
some of the features of the basal group [13], underlining the
heterogeneity of these lesions. In addition, Japaze and co-
authors [14] have recently deﬁned histopathological criteria
for the diagnosis of pure invasive apocrine carcinoma (PIAC),
an intermediate group of apocrine tumours representing a dis-
tinct clinicopathological entity. These lesions have a less
aggressive behaviour than invasive ductal carcinomas other-
wise not speciﬁed (IDC-NOS) [14]. In summary, given the lack
of criteria, histological as well as molecular, to reproducibly
categorize apocrine breast carcinoma and the continuing con-
troversy over its deﬁnition, one cannot determine with cer-
tainty the true clinical signiﬁcance of these lesions.
Our laboratories are part of a multidisciplinary and long-
term research initiative aimed at the comprehensive analysis
of breast cancer lesions using multiple experimental paradigms
from proteomics and functional genomics to study fresh mam-
mary tumours and matched benign tissues, along with the inte-
gration of the multiplatform ‘‘omic’’ data sets with clinical
data from each patient [15–20]. In this minireview we focus
on novel proteomic strategies employed by our laboratories
that have (i) shed some light as to the origin and phenotype
of apocrine carcinomas, (ii) aided in the identiﬁcation of pre-
cancerous lesions in the linear histological model of breast can-
cer progression [21], and (iii) revealed speciﬁc targets for
chemoprevention [20]. Published results as well as new data
are reviewed here and set in the context of the current state
of research on breast apocrine cancer.2. Origin of apocrine tumours: relationship between benign
apocrine metaplasia and apocrine carcinomas
Apocrine diﬀerentiation of breast epithelial cells has at-
tracted a great deal of attention as up to 50% of breast invasive
carcinomas exhibit areas with apocrine morphology features
[22–28], and because available data have shown that women
with breast apocrine cystic disease have an increased propen-
sity for developing breast cancer later in their lives [29–33].
Presently, little is known about the molecular mechanisms
underlying apocrine metaplasia, a process that entails the con-
version of breast epithelial cells in the terminal duct lobular
units (TDLUs) into sweat gland type cells [34]. Breast apocrine
cells are cytologically identical to cells in apocrine glands in
that they exhibit rather large vesicular nuclei with prominent
nucleoli, as well as abundant eosinophilic cytoplasm that occa-
sionally present apical snouts that are shed into the lumen of
the ducts [29,35–37]. Apocrine lesions are usually diagnosed
based on morphological features [27] and their relationship
with invasive disease remains controversial as diﬀerent authors
have described these lesions as either a precursor in malignant
apocrine transformation, or as benign lesions with no correla-
tion with malignancy [24,29,35,37,39–44]. Up to one third of
the women aged 30–50 bear large apocrine cysts in their
breasts [29,36], and both their frequency and their proposed
association with an increased risk of breast cancer have under-
pinned the importance of investigating these lesions at themolecular level in order to enlighten their putative relationship
with invasive disease, in particular apocrine carcinoma
[13,20,37,45].
The strategy we have used to unravel the relationship be-
tween benign apocrine metaplastic epithelium and invasive
apocrine cancer was based on the assumption that invasive
apocrine carcinomas evolve from epithelial cells in TDLU’s
in a stepwise manner, going through diﬀerent sequential stages
that involve metaplasia, hyperplasia, atypia, and carcinoma
in situ (CIS) [21,37,46]. Firstly, we derived speciﬁc protein bio-
markers for benign apocrine metaplasia by comparing the pro-
tein expression proﬁles of non-malignant breast epithelia and
apocrine cells. Secondly, we generated speciﬁc antibody probes
against these markers to use in immunohistochemistry (IHC)
based analysis of tissue specimens to determine if these mark-
ers were indeed expressed by apocrine carcinomas [20].2.1. Apocrine diﬀerentiation of breast epithelial cells:
identiﬁcation of speciﬁc biomarkers of apocrine metaplasia
Gross cystic disease is the most commonly observed benign
disease of the breast occurring in about 7% of all adult women
[47]. Cysts are divided into apocrine – or type I, ﬂattened – or
type II, and intermediate types based on the K+/Na+ concen-
tration ratio [31,48–51]. Type I cysts (apocrine) have a higher
K+/Na+ ratio (P1.5) [48], and are lined by metaplastic apocrine
secretory epithelium that exhibit tight cell–cell junctions. The
conversion of breast epithelial cells to apocrine cells is a com-
mon phenomenon in the female breast, with microscopic apo-
crine changes appearing, typically, after the age of 30 and
increasingly thereafter [29,36]. Apocrine microcysts are derived
by either: (i) cystic transformation of glandular cells, followed
by dilation of the ductules due to secretion, (ii) metaplasia of
larger ducts, or (iii) by apocrine metaplasia of intraductal pap-
illary lesions [20,45,52–54]. Microcysts can enlarge to become
macrocysts reaching sizes of a couple of cm’s in diameter, caus-
ing pain and discomfort due to the tension eﬀects on the sur-
rounding stroma. We have recently presented evidence
indicating that apocrine macrocysts arise by coalescence of
smaller microcysts [20]. Apocrine macrocysts are heteroge-
neous in their cytological characteristics and in some cases
present transitions from cuboidal to ﬂat apocrine epithelia,
most likely representing diﬀerences in their stage of diﬀerenti-
ation and/or metabolic activity.
Apocrine micro- and macrocysts do not express estrogen
receptor alpha (ER-alpha) and progesterone receptor (PR)
[55–57], but are positive for the androgen receptor (AR) and
Her-2 Neu [13,20]. In addition, these lesions exhibit a low pro-
liferative index as determined by staining with the Ki67 anti-
body [20,56].
To generate speciﬁc biomarkers of apocrine metaplasia we
compared the protein expression proﬁles of fresh breast apo-
crine macrocysts with those of matched non-malignant tissues
collected from the same patient [20] as these lesions are rela-
tively large in size and provide abundant material for gel-based
protein analysis. By combining an improved tissue sample
preparation procedure that allows the proteomic analysis of
only a few cryostat sections under a well-deﬁned histological
framework (Fig. 1) [19,20] with two-dimensional polyacryl-
amide gel electrophoresis (2D PAGE) and mass spectrometry,
we have identiﬁed several proteins that are expressed preferen-
tially, or solely by apocrine cells (Fig. 2A and B) [20]. These
Fig. 1. Overview of the various steps involved in the analysis of apocrine macrocysts. A similar procedure was used to analyze non-malignant and
tumour specimens.
Fig. 2. IEF 2D PAGE of lysates of cryo sections from (A) apocrine macrocyst and (B) non-malignant epithelia from the same patient. Proteins that
are preferentially expressed by the apocrine cyst are indicated with their respective names.
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3-hydroxymethylglutaryl CoA synthase (HMG-CoA synthase),
gross cystic disease ﬂuid protein-15 (GCDFP-15), apolipopro-
tein D (Apo D), apolipoprotein J (Apo J), beta-glucuronidase,
steroid carrier-binding protein 2 (SCP2), ﬂavin reductase,
aldo–keto reductase familly 1, CuZn–superoxide dismutase
(CuZn–SOD), brain fatty acid binding protein (B-FABP),
cathepsin D, and heat shock protein 27 (hsp 27). Most of the
expression changes observed by 2D PAGE analysis were vali-
dated by IHC, with some examples being presented in Fig. 3A–
N. In addition, we surmised two other biomarkers from ourdata, HMG-CoA reductase, a protein that is coordinately ex-
pressed with HMG-CoA synthetase [58,59] (Fig. 3P), and
cyclooxygenase 2 (COX-2) [60], a 15-PGDH antagonist activ-
ity (results not shown), both of which were shown by IHC to
be up-regulated in apocrine cells and present in micro and
macrocysts [20]. An annotated 2D gel image of all the apocrine
cyst proteins identiﬁed so far will be made available through
our website (http://proteomics.cancer.dk).
Of all the up regulated proteins we identiﬁed, only 15-PGDH
(Fig. 3B) and HMG-CoA reductase (Fig. 3P) are expressed spe-
ciﬁcally by apocrine cysts, and by apocrine metaplastic cells
Fig. 3. IHC pictures of apocrine microcysts and non-malignant breast tissues reacted with antibodies against proteins expressed preferentially, or
solely by apocrine cells. The peptide antibodies against GCDFP-15, Apo J, Apo D, ﬂavin reductase, and CuZn-SOD were prepared by Eurogentec.
The antibodies against aldo–keto reductase family 1 and the HMG-CoA reductase were a kind gift of R.J. Cenedella (Kirksville, Mo) and H.
Aburatani (Tokyo), respectively. The antibodies against 15-PGDH were prepared in the laboratory and have been described before [20].
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lary lesions [20]. IHC analysis of hundreds of sections of non-
malignant tissue biopsies collected from 93 patients with
invasive breast cancer showed that these markers are not ex-
pressed by cells present in non-malignant terminal ductal lobu-
lar units (TDLUs) (Fig. 3A), type II ﬂat microcysts, stroma
(Fig. 3A), fat tissue, or any other cell type of mammary tissue
examined [20], underscoring their value as speciﬁc markers
for apocrine lesions. These biomarkers are far superior for dis-
crimination of apocrine cells compared to GCDFP-15, a pro-
tein generally regarded as a speciﬁc functional marker of
apocrine cells [61], which cannot be used alone to pinpoint apo-
crine lesions as it is expressed by some non-apocrine breast epi-
thelial cells [20,37,62].
2.2. Expression of speciﬁc apocrine metaplasia biomarkers by
pure invasive apocrine carcinomas establish a direct link
between these lesions
An important question that has been debated for some years
concerns the relationship between apocrine changes and breast
carcinoma, in particular apocrine carcinoma [29,38,40,41,43,
44]. So far, published studies have shown contradictory resultsas apocrine lesions have been considered as either a precursor in
malignant apocrine transformation, or as benign lesions with
no correlation with malignancy [24,29,35, 37,39–44].
Having demonstrated the strict speciﬁcity of our antibody
probes recognizing 15-PGDH and HMG-CoA reductase anti-
gens, we analyzed by IHC 93 prospective breast tumour samples
for which we had collected proteomic data during a period of
three years [16,17,19,20]. These studies revealed that only one
of the lesions, classiﬁed by the attending pathologist as inva-
sive pure apocrine carcinoma (RH-79), expressed 15-PGDH
(Fig. 4A), although no HMG-CoA reductase could be de-
tected. These results are in harmony with the fact that our
set of tumours, consisting of 75 invasive ductal carcinomas,
15 invasive lobular carcinomas, one mucinous carcinoma,
one tubular lesion, and one single apocrine carcinoma, reﬂect-
ing the expected incidence of mammary tumour types preva-
lent in the general population [63,64].
Since the expression of 15-PGDH by an invasive apocrine
carcinoma suggested a link between benign apocrine metapla-
sia and the tumour phenotype, we proceeded to analyze by
IHC and 2D PAGE six retrospective pure apocrine carcinomas
for which we had snap-frozen tissue and paraﬃn-embedded
Fig. 4. IHC staining and 2D PAGE of invasive breast carcinomas. (A) Pure apocrine carcinoma RH-79 reacted with the 15-PGDH antibody. (B)
and (C) Ductal and lobular invasive carcinomas reacted with the 15-PGDH antibody. (D) Invasive area of apocrine carcinoma RH-34697 reacted
with the 15-PGDH antibody. (E) as (D), but depicting an area with apocrine CIS. (F) Invasive area of apocrine carcinoma RH-21990 reacted with
the HMG-CoA reductase antibody. (G) as (F), but depicting an area with apocrine CIS. (H) Silver stained 2D gel of whole lysates from pure apocrine
carcinoma RH-9777. (I) Silver stained 2D gel of whole lysates from pure apocrine carcinoma RH-21990. (J) Silver stained 2D gel of whole lysates
from the apocrine cyst shown in Fig. 2A.
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15-PGDH antibody, which decorated both invasive (Fig. 4D)
and CIS apocrine cells (Fig. 4E; RH-34697). All ﬁve apocrine
cancers were ER-alpha and PR negative, AR positive, while
four were p53 positive [20]. Interestingly, only one of the 15-
PGDH positive tumours (RH-34697) expressed HMG-CoA
reductase both in the invasive and CIS apocrine cells (results
not shown), while another (RH-21990) expressed the enzyme
solely in the CIS apocrine cells (Fig. 4F, compare with G) sug-
gesting that in some lesions expression of HMG-CoA reduc-
tase may be lost prior to 15-PGDH during cancer
progression. Expression of 15-PGDH by ﬁve out of the six
pure apocrine carcinomas was conﬁrmed by gel-based proteo-
mic analysis of frozen cryostat sections (Fig. 4H). The apo-
crine tumour that failed to express 15-PGDH (RH-24678),
determined both by IHC and 2D PAGE (results not shown)
may represent a more advanced apocrine carcinoma.
Given that 15-PGDH is not expressed by any other breast
tumour type as judged both by IHC (Fig. 4B and C) and 2D
PAGE analysis (results not shown) [20], the results are taken
to imply that there is a direct link between benign apocrine
metaplasia and apocrine cancer. The results, however, also
indicated that most apocrine changes have little intrinsic
malignant potential, although some lesions may progress to
invasive apocrine cancer. At present we do not know which
apocrine lesions will progress to invasive disease, and therefore
there is an urgent need to develop novel strategies to reveal andcharacterize at the molecular level the early spectrum of lesions
in the linear histological progression from normal epithelial
breast cells to invasive disease. Our initial eﬀorts in this direc-
tion are summarized below.3. Early stages in apocrine cancer progression: a protein
expression signature for benign apocrine metaplasia
In order to reveal early precancerous apocrine lesions (aty-
pia and CIS) it is necessary to identify protein markers that
are expressed by pure apocrine carcinomas but are absent in
benign apocrine lesions. Antibodies against these malignancy
speciﬁc markers in combination with already available apo-
crine-speciﬁc antibodies are expected to provide powerful tools
to identify early apocrine lesions using IHC in combination
with immunowalking, i.e staining of consecutive sections with
various antibodies [65].
Comparison of the protein proﬁles of apocrine macrocysts
with those of pure invasive apocrine carcinomas have, so far,
revealed two proteins expressed by the tumours, albeit at dif-
ferent levels, that are absent in the benign apocrine lesions.
These are psoriasin (S100A7) [66] and S100A9 (MRP-14, cal-
granulin B) [67] (compare Fig. 4I and J), both members of
the S100 family of proteins [68,69]. These results have been val-
idated by IHC using speciﬁc antibodies (results not shown).
Psoriasin has been shown to play a role in the progression of
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enhancing the selection for cells that overcome its anti-invasive
function [70]. S100A9 on the other hand is known to be dereg-
ulated in several cancers [71–73], but its speciﬁc function is at
present unknown. Both psoriasin and S100A9 are expressed by
other breast tumour types, but the fact that most pure apocrine
lesions express 15-PGDH is expected to facilitate the identiﬁ-
cation of early lesions that are of apocrine origin.
Based on the proteomic and IHC analysis of numerous apo-
crine cysts, non-malignant breast tissue, and pure apocrine le-
sions we have deﬁned a protein expression signature that we
believe characterises benign apocrine metaplasia. This signa-
ture, which consists of 15-PGDH (+), HMG-CoA reductase
(+), p53 (), psoriasin (), and S100A9 () (Fig. 5A–D),Fig. 5. IHC staining of benign apocrine metaplasia and various apocrine at
against components of the expression signature. (A–D) Benign metaplasia. (E
Tumour RH-71. With the exception of U, all others correspond to serial se
Eurogentec. The psoriasin monoclonal antibody has been previously describmay prove valuable for diagnosing benign apocrine metapla-
sias both in paraﬃn sections and in ﬁne needle aspiration
cytology. Moreover, antibodies against the components of
the expression signature oﬀer unique tools to search for pre-
cancerous lesions using IHC in combination with immuno-
walking as described below [65].
3.1. Towards the identiﬁcation of precancerous apocrine lesions
The assumption that invasive apocrine carcinomas evolve
from epithelial cells in TDLU’s in a progressive stepwise man-
ner has been a key element in our work, even though we realise
that this may be a simpliﬁcation. An upshot of this assumption
is that in the progression from precancerous to invasive lesions,
the proteome of cells will inevitably change with expression ofypias detected in the invasive area of tumour RH-71 using antibodies
–H) Atypia 1. (I–L) Atypia 2. (M–P) Atypia 3. (Q–T) Atypia 4. (U–X)
ctions. The antibody against S100A9 (EPO 010100) was prepared by
ed [85].
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that levels of apocrine-speciﬁc biomarkers change during
apocrine cancer progression was provided by the observation
that in one pure apocrine tumour examined (RH-21990) the
CIS lesions were positive for HMG-CoA reductase (Fig. 4G),
while the invasive component was negative (Fig. 4F) [20]. This
result encouraged us to carry out a search for early lesions by
probing a large number of apocrine lesions with antibodies
against the components of the benign apocrine expression sig-
nature we had derived, using IHC in combination with immu-
nowalking [65]. Using this approach we expect to be able to
characterize the various histological stages involved in apocrine
carcinoma progression.
One example of the outcome of this approach and that we
believe validates it is shown in Fig. 5E–T which depict atypias
present in the invasive area of a breast tumour (RH-71) that
was 15- PGDH and HMG-CoA reductase negative, and psori-
asin, S100A9 and p53 positive (Fig. 5U–X).
Atypia 1:
Apocrine cells in this atypia stained strongly with the 15-
PGDH (Fig. 5E) and HMG-CoA reductase (Fig. 5F) antibod-
ies, while some cells expressed p53 (results not shown). None
of the cells however, expressed psoriasin (Fig. 5G) or
S100A9 (Fig. 5H).
Atypia 2:
This atypia (arrows in Fig. 5I–L) is very similar to atypia 1,
with the exception that cells expressed low levels of HMG-
CoA reductase (Fig. 5J) in line with the observation described
in Fig. 4F that suggested that the expression of this enzyme
may be lost early during apocrine cancer progression in some
lesions. Some cells expressed p53 (results not shown), but there
was no expression of psoriasin (Fig. 5K) or S100A9 (Fig. 5L).
Atypia 3:
This atypia is like atypia 2, except that the cells express both
psoriasin (Fig. 5O) and S100A9 (Fig. 5P). We have also ob-
served cells that express only S100A9 (red arrows in Fig. 5O
and P)
Atypia 4:
In this atypia most of the cells were negative for 15-PGDH (ar-
row in Fig. 5Q) and HMG-CoA reductase (Fig. 5R). Many
cells were positive for p53 (results not shown), psoriasin
(Fig. 5S), and S100A9 (Fig. 5T).
Given the low number of specimens analyzed so far it is not
possible at this stage to draw a reliable conclusion concerning
the phenotype continuity of the atypias, or if any of them will
progress to invasive disease. To achieve this goal it will be nec-
essary to identify additional biomarkers that are lost or gained
during early cancer progression. These studies, which are cur-
rently underway, will greatly beneﬁt from the analysis of biop-
sies obtained from patients with apocrine CIS as these
sometime exhibit a whole range of atypias, as well as normal
epithelia.4. Targets for chemoprevention
The identiﬁcation of diﬀerentially expressed proteins that
characterize a speciﬁc step in the progression from early benign
lesions to apocrine cancer has opened a window of opportu-
nity for designing and testing new approaches for pharmaco-
logical intervention. Some of the biomarkers we identiﬁed as
being expressed by apocrine metaplasias such as 15-PGDH,HMGCoA reductase, and COX-2, are well known therapeutic
targets [74–78] with pharmacological agents already available
(e.g. pravastatin, lovastatin, Ph CL 28A, nafazatrom, cele-
coxib, and rofecoxib). In at least one case, that of COX-2,
one has reason to suspect a causal relationship [79] to the
development of ﬁbrocystic changes, making a case for the
use of COX-2 inhibitors as chemopreventing agents for breast
cyst formation and development. Further studies into the func-
tional role that the various biomarkers identiﬁed in this study
play in cyst formation are warranted, as they may identify
therapeutic targets for ﬁbrocystic changes and premalignant
apocrine lesions.5. Concluding remarks
The studies reviewed here were undertaken in an eﬀort to
dissect and gain a better understanding of the steps leading
to breast apocrine metaplasia, and ultimately intended to gen-
erate speciﬁc biomarkers that may enlighten its relationship
with cancer phenotype. As a whole, the results indicate that
most apocrine changes have little intrinsic malignant potential,
although a few lesions may progress to apocrine carcinoma.
None of these lesions, however, seems to be a precursor of
invasive ductal carcinomas, which accounted for 81% of the
tumours analyzed.
All available information indicates that apocrine tumours of
the breast comprise a heterogeneous group of lesions that may
evolve through diverse molecular pathways. Indeed, studies
from Japaze and colleagues [14] indicate that pure apocrine
carcinomas correspond to a distinct clinicopathological entity
exhibiting a less aggressive behaviour than high grade IDC-
NOS, and Farmer and colleagues [13] described a novel group
of breast cancer tumours that they designated ‘‘molecular
apocrine’’ and that comprised between 8% and 14% of all
the tumours analyzed in their microarray study as well as in
four published breast cancer datasets [12,80–82]. The latter
data implies that apocrine tumours may be more frequent
than previously thought from current diagnostic procedures
using histopathological criteria alone. Molecular apocrine tu-
mours diﬀer from other tumour types by the expression of sev-
eral genes, including HMG-CoA reductase in line with our
studies. Surprisingly, however, 15-PGDH was not detected in
Farmer’s study, a fact that most likely reﬂects diﬀerences be-
tween transcriptomics and proteomics approaches [83,84].
Clearly, renewed eﬀorts should be made to identify markers
for more advanced apocrine carcinomas as not all of these
lesions may be positive for the apocrine speciﬁc markers we
have identiﬁed.
To dissect all of the stages involved in apocrine carcinoma
progression., i.e., from benign metaplasia to hyperplasia, aty-
pia, CIS, and invasive cancer, it will be necessary to identify
not only those biomarkers that are lost through cancer pro-
gression, but also those that appear early in carcinogenesis.
This will require the proteomic analysis of many tissue samples
in prospective studies, as well as the preparation of speciﬁc
antibody probes that could be used in immunohistochemical
analysis of archival samples. In the long-run the outcome of
these studies may provide speciﬁc probes that will permit accu-
rate pre-operative diagnosis as well as for complementing the
analysis of cells and cyst ﬂuid found by ﬁne needle aspiration
cytology of patients attending the mammography clinic.
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